Glenmark Pharmaceuticals receives ANDA tentative approval for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by the United States Food & Drug Administration (U.S. FDA) for Dapagliflozin and Saxagliptin Tablets, 10 mg/5 mg, the generic version of Qtern®1 Tablets, 10 mg/5 mg, of AstraZeneca AB.

According to IQVIATM sales data for the 12 month period ending February 2020, the Qtern® Tablets, 10 mg/5 mg market2 achieved annual sales of approximately $10.4 million*.

Glenmark’s current portfolio consists of 162 products authorized for distribution in the U.S. marketplace and 44 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Also Read:   Zydus Cadila receives final approval from USFDA for Atazanavir Capsules

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.329.7 as compared to the previous close of Rs. 327.8. The total number of shares traded during the day was 134635 in over 3555 trades.

The stock hit an intraday high of Rs. 335.2 and intraday low of 325.9. The net turnover during the day was Rs. 44565697.

1All brand names and trademarks are the property of their respective owners.
2Market includes brand and all available therapeutic equivalents
*IQVIATM National Sales Perspectives: Retail & Non-Retail, February 2020